市场调查报告书
商品编码
1541386
2024-2032 年按类型、治疗方法、最终用户和地区分類的血液恶性肿瘤市场报告Hematologic Malignancies Market Report by Type, Therapy, End User, and Region 2024-2032 |
IMARC Group年,全球血液恶性肿瘤市场规模达到603亿美元。血癌盛行率不断上升、越来越多地采用针对基因特征的标靶疗法和免疫疗法,以及专注于血液癌症新疗法的生物製药管道的扩展是推动市场成长的一些关键因素。
主要市场驱动因素:血液恶性肿瘤发生率上升,加上人口老化,正在推动对血液恶性肿瘤药物的需求。此外,人们对早期诊断的认识不断增强,以及诊断方式的改进,也促进了市场的成长。
主要市场趋势:标靶治疗、免疫疗法和个人化医疗的创新正在改变血液癌症患者的治疗选择、改善结果并减少副作用,是促进血液恶性肿瘤市场收入的重要因素之一。
竞争格局:在全球市场运营的一些领先公司包括艾伯维公司、阿斯特捷利康公司、百时美施贵宝公司、礼来公司、罗氏公司、葛兰素史克公司、强生公司、默克公司. Inc. 、诺华公司、辉瑞公司、赛诺菲公司和武田製药有限公司等。
地理趋势:血液恶性肿瘤市场在全球呈现强劲成长。在北美,这种增长可归因于先进的医疗基础设施和高发病率。欧洲紧随其后,在研发方面进行了大量投资。在医疗保健支出增加和获得先进治疗的机会增加的推动下,亚太地区正在迅速崛起,从而促进了市场扩张。
挑战与机会:血液恶性肿瘤市场面临治疗成本高、疾病生物学复杂、个人化治疗需求等挑战。然而,在推进标靶治疗、免疫疗法和诊断技术方面存在机会,以改善患者的治疗结果并满足对有效和个人化癌症护理解决方案不断增长的需求。
血癌盛行率上升
血癌发病率不断上升以及对新疗法开发的日益重视主要推动了血液恶性肿瘤市场的成长。根据 Globocan 2020 的数据,亚洲的白血病发病率估计最高,2020 年诊断出 230,650 例,其次是欧洲 100,020 例,北美 67,784 例。因此,全球白血病的高发生率预计将推动血液恶性肿瘤市场的成长。同样,根据全球癌症观察站的数据,2020 年,北美地区报告了近 67,784 例白血病病例和估计 35,318 例多发性骨髓瘤病例。据白血病和淋巴瘤协会称,2021 年,美国估计共有 397,501 人患有白血病或处于缓解期。因此,市场上血癌病例的显着增加预计将在预测期内推动血液恶性肿瘤的市场价值。
越来越多的产品发布、合作伙伴关係和协作
许多公司正在实施各种策略性倡议,例如推出新产品、建立合作伙伴关係、促进合作以及进行併购,以增强其市场影响力。这反过来又对血液恶性肿瘤市场前景产生正面影响。例如,2020年10月,阿斯特捷利康印度製药公司宣布推出Acalabrutinib 100 mg胶囊,用于治疗各类白血病(白血病(CLL)和小淋巴细胞淋巴瘤),品牌为Calquence。同样,2024年1月,塔塔纪念医院开发出印度第一个治疗白血病的口服化疗药物。这项突破性的发展有望彻底改变癌症治疗,特别是像急性淋巴性白血病(ALL)这样的血液恶性肿瘤,为传统药片提供更精确、更适合儿童的替代品。预计此类创新将在未来几年增加血液恶性肿瘤市场的需求。
增加产品批准
各个相关监管机构越来越多地批准血液恶性肿瘤药物,这为整体市场创造了积极的前景。例如,2020年9月,美国FDA核准百时美施贵宝的氮胞苷(Onureg)300毫克片剂CC-486继续治疗成人急性髓性白血病患者。同样,2021 年 3 月,赛诺菲 SA 的 Sarclisa(isatuximab)联合卡非佐米和地塞米松治疗復发或难治性多发性骨髓瘤患者获得美国 FDA 批准。与此一致,2021年2月,TG Therapeutics Inc.的UKONIQ(umbralisib)获得美国FDA加速批准,这是一种口服、每日一次的磷酸肌醇3激酶(PI3K)δ和酪蛋白激酶1( CK1)ε抑制剂,用于治疗治疗患有復发或难治性边缘区淋巴瘤(MZL)的成人患者和患有復发或难治性滤泡性淋巴瘤(FL)的成人患者。批准用于治疗血癌的药物数量的显着增长正在推动血液恶性肿瘤的市场价值。
The global hematologic malignancies market size reached US$ 60.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 122.4 Billion by 2032, exhibiting a growth rate (CAGR) of 7.9% during 2024-2032. Growing prevalence of blood cancer, increasing adoption of targeted therapies and immunotherapies tailored to genetic profiles, and expansion of biopharmaceutical pipelines focusing on novel treatments for hematologic cancers are some of the key factors driving the growth of the market.
Major Market Drivers: The rising incidence of hematologic malignancies, coupled with an aging population, is driving demand for hematologic malignancy drugs. Additionally, the growing awareness about early diagnosis, along with improving diagnostic modalities, is also contributing to market growth.
Key Market Trends: Innovations in targeted therapies, immunotherapy, and personalized medicine, which are transforming treatment options, improving outcomes, and reducing side effects for patients with hematologic cancers, refer to one of the significant factors catalyzing the hematologic malignancies market revenue.
Competitive Landscape: Some of the leading companies operating in the global market include AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited, among many others.
Geographical Trends: The hematologic malignancies market shows strong growth globally. In North America, the growth can be attributed to the advanced healthcare infrastructure and high incidence rates. Europe follows with significant investments in research and development. Asia-Pacific is emerging rapidly, driven by increasing healthcare expenditure and improving access to advanced treatments, fostering market expansion.
Challenges and Opportunities: The hematologic malignancies market faces challenges such as high treatment costs, complex disease biology, and the need for personalized therapies. However, opportunities exist in advancing targeted therapies, immunotherapies, and diagnostic technologies to improve patient outcomes and meet the growing demand for effective and personalized cancer care solutions.
Rising Prevalence of Blood Cancer
Escalating incidences of blood cancer and a growing emphasis on the development of new treatments are primarily driving the growth in the hematologic malignancies market. According to Globocan 2020, the estimated incidence of leukemia was the highest in Asia, with 230,650 cases diagnosed in 2020, followed by 100,020 cases in Europe and 67,784 cases in North America. Thus, the high incidence of leukemia worldwide is expected to drive the hematologic malignancies market growth. Similarly, according to the Global Cancer Observatory, in 2020, nearly 67,784 cases of leukemia and an estimated 35,318 cases of multiple myeloma were reported in the North American region. According to the Leukemia and Lymphoma Society, in 2021, an estimated combined total of 397,501 people in the United States were living with or in remission from leukemia in the United States. Thus, a prominent rise in blood cancer cases in the market is expected to propel the hematologic malignancies market value over the forecasted period.
Growing Number of Product Launches, Partnerships, and Collaborations
Numerous companies are implementing diverse strategic initiatives such as launching new products, forming partnerships, fostering collaborations, and engaging in mergers and acquisitions to enhance their market presence. This, in turn, is positively impacting the hematologic malignancies market outlook. For instance, in October 2020, AstraZeneca Pharma India announced the launch of Acalabrutinib 100 mg capsules, which are used for the treatment of various types of leukemias (leukemia (CLL) and small lymphocytic lymphoma) under the brand name Calquence. Similarly, in January 2024, Tata Memorial Hospital developed India's first oral chemo drug for Leukaemia. This groundbreaking development is poised to revolutionize cancer treatment, specifically hematologic malignancies like Acute Lymphoblastic Leukaemia (ALL), providing a more precise and child-friendly alternative to traditional tablets. Such innovations are projected to augment the hematologic malignancies market demand in the coming years.
Increasing Product Approvals
Various concerned regulatory authorities are increasingly approving hematologic malignancies drugs, which is creating a positive outlook for the overall market. For instance, in September 2020, the US FDA approved Bristol Myers Squibb's azacytidine (Onureg) 300 mg tablets, CC-486, to continue treating adult patients with acute myeloid leukemia. Similarly, in March 2021, Sanofi SA received US FDA approval for its Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma. In line with this, in February 2021, TG Therapeutics Inc. received the US FDA accelerated approval for its UKONIQ (umbralisib), an oral, once-daily inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) and adult patients with relapsed or refractory follicular lymphoma (FL). Significant growth in number of approved drugs for treating blood cancer is propelling the hematologic malignancies market value.
IMARC Group provides an analysis of the key trends in each segment of the global hematologic malignancies market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on type, therapy, and end user.
Leukemia
Lymphoma
Multiple Myeloma
Others
The hematologic malignancies market report has provided a detailed breakup and analysis of the market based on the type. This includes leukemia, lymphoma, multiple myeloma, and others.
Leukemia is a type of hematologic malignancy, also known as blood cancer, that originates in the bone marrow and affects the production of blood cells. The rising cases of leukemia across the globe are bolstering the hematologic malignancies market share. According to Globocan 2020, the estimated incidence of leukemia was the highest in Asia, with 230,650 cases diagnosed in 2020, followed by 100,020 cases in Europe and 67,784 cases in North America.
Furthermore, the significant rise in the multiple myeloma market is a clear indication of the need for increased research and development. For instance, according to the Global Cancer Observatory, in 2020, nearly 35,318 cases of multiple myeloma were reported in the North American region. This rise in multiple myeloma cases underscores the importance of your work and is positively influencing the hematologic malignancies market price trends.
Chemotherapy
Radiotherapy
Immunotherapy
Stem Cell Transplantation
Others
The report has provided a detailed breakup and analysis of the market based on the therapy. This includes chemotherapy, radiotherapy, immunotherapy, stem cell transplantation, and others.
As per the hematologic malignancies market overview by IMARC, for most types of blood cancers, chemotherapy is the common treatment. The large patient pool and the increasing incidence of blood cancers are the major drivers augmenting the need for chemotherapy. For instance, in June 2019, the United States Food and Drug Administration granted approval to Polivy to be used in combination with the chemotherapy drug bendamustine and rituximab to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.
Hospitals
Diagnostics Centers
Research Centers
Others
The hematologic malignancies market research report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, diagnostics centers, research centers, and others.
Hospitals are primary end users in the hematologic malignancies market, providing diagnosis, treatment, and ongoing care for patients with blood cancers, such as leukemia, lymphoma, and myeloma. They offer a range of specialized services, including chemotherapy, radiation therapy, stem cell transplantation, and supportive care. Hospitals also serve as centers for clinical trials and research, driving advancements in treatment options and patient outcomes.
Diagnostics centers are essential for early detection and monitoring of hematologic malignancies through a variety of tests, including blood tests, bone marrow biopsy, imaging studies, and genetic testing. These centers provide accurate diagnostic services, enabling healthcare providers to initiate timely treatment strategies. Diagnostics centers often collaborate closely with hospitals and oncology clinics to ensure comprehensive patient care and management throughout the treatment journey.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
The hematologic malignancies market shows strong growth globally. In North America, the growth can be attributed to the advanced healthcare infrastructure and high incidence rates. Europe follows with significant investments in research and development. Asia-Pacific is emerging rapidly, driven by increasing healthcare expenditure and improving access to advanced treatments, fostering market expansion.
Besides this, hematologic malignancies market statistics indicates that the presence of key players, the high prevalence of blood cancer patients, established healthcare infrastructure, and the availability of branded drugs in North America and Asia Pacific countries are positively impacting the hematologic malignancies industry. According to the Global Cancer Observatory, in 2020, nearly 67,784 cases of leukemia and an estimated 35,318 cases of multiple myeloma were reported in the North American region. As per the Leukemia and Lymphoma Society, in 2021, an estimated combined total of 397,501 people in the United States were living with or in remission from leukemia in the United States. Thus, the increasing number of blood cancer cases in the region is a major driving factor for the growth of the market. Besides this, hematologic malignancies market forecast by IMARC indicates that beneficial government initiatives and an increase in the number of research partnerships are further contributing to the market growth. For instance, in December 2020, the Leukemia and Lymphoma Society (LLS) initiated a collaboration to form alliances with leading cancer institutions and foundations to co-fund nearly US$ 17 Million in research grants to progress the research in finding effective treatment options for patients with leukemia, lymphoma, myeloma, and other blood cancers.
AbbVie Inc.
AstraZeneca plc
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co. Inc
Novartis AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
June 2024: The University of Cincinnati Cancer Center launched a new treatment center dedicated specifically to blood cancers. It is the university's first state-of-the-art center devoted to blood cancer care in the United States.
June 2024: Fortis inaugurated a state-of-the-art facility for the specialized treatment of blood cancers and disorders.
January 2024: Tata Memorial Hospital developed India's first oral chemo drug for Leukaemia. This groundbreaking development is poised to revolutionize cancer treatment, specifically hematologic malignancies like Acute Lymphoblastic Leukaemia (ALL), providing a more precise and child-friendly alternative to traditional tablets.